Invention Grant
- Patent Title: Porphyrin compound or salt thereof, cancer therapeutic agent, photosensitizer, and fluorescent probe
-
Application No.: US17462279Application Date: 2021-08-31
-
Publication No.: US11643430B2Publication Date: 2023-05-09
- Inventor: Hiroaki Horiuchi , Masahiko Oshige , Ichiro Matsuo , Tetsuo Okutsu , Shinji Katsura , Toshitada Yoshihara , Seiji Tobita , Fumio Sugawara , Kengo Sakaguchi
- Applicant: M.T.3, Inc. , NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
- Applicant Address: JP Tokyo
- Assignee: M.T.3, INC.,NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
- Current Assignee: M.T.3, INC.,NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
- Current Assignee Address: JP Tokyo; JP Maebashi
- Agency: Buchanan, Ingersoll & Rooney PC
- Priority: JP 2020146971 2020.09.01
- Main IPC: C07H17/02
- IPC: C07H17/02 ; A61K41/00
Abstract:
There is provided with a porphyrin compound represented by Formula (I) or a salt thereof;
where A is a linking group represented as —X—NHCO— where X is a C1 to C6 alkylene group, each of R1, R2, R4, R5, R7, R8, R10, and R11 is a hydrogen atom, each of R3, R6, and R9 is a substituent of Formula; R12 is selected from a group of substituents represented by Formulae, R13 is a sulfo group, Ra, Rb, and Rc are substituents independently selected from C1 to C6 alkyl groups, and Rd is a hydrogen atom or a C1 to C6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.
where A is a linking group represented as —X—NHCO— where X is a C1 to C6 alkylene group, each of R1, R2, R4, R5, R7, R8, R10, and R11 is a hydrogen atom, each of R3, R6, and R9 is a substituent of Formula; R12 is selected from a group of substituents represented by Formulae, R13 is a sulfo group, Ra, Rb, and Rc are substituents independently selected from C1 to C6 alkyl groups, and Rd is a hydrogen atom or a C1 to C6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.
Public/Granted literature
- US20220064203A1 COMPOUND OR SALT THEREOF, AND METHOD Public/Granted day:2022-03-03
Information query
